Ojemda® approved in the EU in R/R pediatric low-grade glioma regardless of BRAF alteration April 28, 2026
ZEPZELCA + Tecentriq approved for use in Australia and Singapore as 1L maintenance treatment for adult patients with ES-SCLC April 21, 2026
Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma April 21, 2026
European Commission Approves KEYTRUDA + Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens April 7, 2026
Japan’s MHLW approves risovalisib (Risovalisib Mesilate Hydrate or Heitzexin) after chemo for ovarian clear cell carcinoma with advanced PIK3CA gene mutations March 31, 2026
FDA Approves Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer March 31, 2026
ENHERTU Followed by THP Approved in China for the Neoadjuvant Treatment of HER2+ve Breast Cancer March 31, 2026
Opdivo combination regimens received FDA approval for previously untreated, Stage III or IV cHL and EC approval in R/R cHL after one prior line of therapy March 24, 2026
Imfinzi approved in the EU in patients with early gastric and gastroesophageal cancers March 17, 2026
European Commission approves AKEEGA (niraparib & abiraterone dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic HSPC patients March 10, 2026
SC RYBREVANT approved by European Commission for Q3W and Q4W dosing for patients with advanced EGFR-mutated NSCLC March 3, 2026
FDA tentatively approves AND Application for Lutetium Lu 177 Dotatate (PNT2003) for the treatment of somatostatin receptor-positive GEP-NETs March 3, 2026
FDA approves monthly RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) in 1L EGFR+ NSCLC February 25, 2026
European Commission grants conditional marketing authorization for ANKTIVA + BCG in BCG-unresponsive NMIBC CIS, with or without papillary tumors February 25, 2026
Calquence + venetoclax approved in the US as oral, fixed-duration combination for 1L CLL patients February 25, 2026
KEYTRUDA and KEYTRUDA QLEX, Plus Paclitaxel ± Bevacizumab, Approved for 2L/3L PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma February 17, 2026
US FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer February 17, 2026
FDA Approves Label Update for Yescarta for R/R Primary Central Nervous System Lymphoma February 9, 2026
FDA Approves Larger Vial Size for Nelarabine IV Administration for the Treatment of T-ALL and T-LBL February 1, 2026
